Douglass Winthrop Advisors LLC grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 2.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 228,829 shares of the medical research company’s stock after acquiring an additional 5,312 shares during the quarter. Amgen comprises approximately 2.4% of Douglass Winthrop Advisors LLC’s investment portfolio, making the stock its 11th largest holding. Douglass Winthrop Advisors LLC’s holdings in Amgen were worth $39,411,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently bought and sold shares of the company. Jackson Grant Investment Advisers Inc. boosted its position in Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after buying an additional 4 shares during the last quarter. Financial Advisory Service Inc. boosted its position in Amgen by 0.3% in the second quarter. Financial Advisory Service Inc. now owns 1,974 shares of the medical research company’s stock valued at $340,000 after buying an additional 5 shares during the last quarter. Capital Advisors Ltd. LLC boosted its position in Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,103 shares of the medical research company’s stock valued at $190,000 after buying an additional 7 shares during the last quarter. Ballentine Partners LLC boosted its position in Amgen by 0.3% in the second quarter. Ballentine Partners LLC now owns 3,441 shares of the medical research company’s stock valued at $620,000 after buying an additional 9 shares during the last quarter. Finally, Investment Partners Ltd. OH ADV boosted its position in Amgen by 0.5% in the second quarter. Investment Partners Ltd. OH ADV now owns 2,192 shares of the medical research company’s stock valued at $377,000 after buying an additional 11 shares during the last quarter. Hedge funds and other institutional investors own 78.13% of the company’s stock.
Amgen Inc. (NASDAQ:AMGN) opened at 175.22 on Wednesday. The company has a 50-day moving average price of $184.39 and a 200 day moving average price of $172.38. The firm has a market capitalization of $127.85 billion, a P/E ratio of 15.96 and a beta of 1.36. Amgen Inc. has a 1-year low of $133.64 and a 1-year high of $191.10.
Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. The company had revenue of $5.77 billion for the quarter, compared to the consensus estimate of $5.75 billion. Amgen had a return on equity of 29.90% and a net margin of 35.54%. Amgen’s quarterly revenue was down .7% compared to the same quarter last year. During the same period in the previous year, the business earned $3.02 earnings per share. Analysts expect that Amgen Inc. will post $12.66 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Friday, November 17th will be given a dividend of $1.15 per share. The ex-dividend date of this dividend is Thursday, November 16th. This represents a $4.60 dividend on an annualized basis and a yield of 2.63%. Amgen’s payout ratio is 41.63%.
Amgen announced that its board has approved a share buyback program on Wednesday, October 25th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical research company to purchase shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its shares are undervalued.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction on Monday, October 9th. The stock was sold at an average price of $185.95, for a total transaction of $283,573.75. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.19% of the stock is currently owned by insiders.
AMGN has been the topic of a number of recent research reports. Mizuho reiterated a “buy” rating and issued a $195.00 target price on shares of Amgen in a research report on Sunday, July 9th. ValuEngine upgraded Amgen from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. Jefferies Group LLC reiterated a “buy” rating and issued a $195.00 target price on shares of Amgen in a research report on Tuesday, July 11th. Cann reiterated a “buy” rating and issued a $203.00 target price (up previously from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. Finally, Argus upped their target price on Amgen from $180.00 to $195.00 and gave the company a “buy” rating in a research report on Thursday, July 27th. Twelve analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $190.03.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
What are top analysts saying about Amgen Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amgen Inc. and related companies.